SWP
REGN icon

Sagespring Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Sagespring Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$519K Sell
833
-179
-18% -$122K 0.01% 514
2026
Q1 		$782K Sell
1,012
-58
-5% -$44.4K 0.01% 387
2025
Q4 		$826K Buy
1,070
+88
+9% +$59.8K 0.02% 341
2025
Q3 		$552K Buy
982
+329
+50% +$186K 0.01% 441
2025
Q2 		$343K Sell
653
-175
-21% -$97.7K 0.01% 539
2025
Q1 		$525K Buy
828
+292
+54% +$201K 0.01% 376
2024
Q4 		$382K Buy
+536
New +$450K 0.01% 408

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Sagespring Wealth Partners's REGN Position: Q2 2026 in Review

Sagespring Wealth Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 18% in Q2 2026, selling an estimated $122K and leaving 833 shares worth $519K. The position accounts for 0.01% of the portfolio, ranked #514.

Sagespring Wealth Partners first reported a position in REGN in Q4 2024 and has held it in 7 quarters since. The position peaked at $826K in Q4 2025. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Sagespring Wealth Partners held 833 shares of Regeneron Pharmaceuticals worth $519K as of Q2 2026.
  • Sagespring Wealth Partners sold 179 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $122K.
  • Regeneron Pharmaceuticals made up 0.01% of Sagespring Wealth Partners's portfolio in Q2 2026, its #514 holding.
  • Sagespring Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Sagespring Wealth Partners's Regeneron Pharmaceuticals position peaked at $826K in Q4 2025.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Sagespring Wealth Partners's 13F filing for Q2 2026, filed 3 Aug 2026.